Norman Ng, Director of Patient Advocacy and Public Affairs of Healthcare Thinkers, shared a post on LinkedIn:
“China launched the Category C Drug List to fill a critical gap in its healthcare reimbursement system.
While Categories A and B cover essential and cost-effective drugs under basic medical insurance, many high-cost, innovative therapies especially for rare diseases or cutting-edge treatments – were left out, forcing patients to pay entirely out-of-pocket.
Category C introduces a new pathway by integrating commercial health insurance to help fund these advanced medicines.
This move aims to:
– Expand access to clinically valuable but expensive drugs
– Reduce financial burden on patients
– Encourage pharmaceutical innovation by improving market incentives
It’s a strategic shift to support innovation while making breakthrough treatments more affordable and accessible.”
More posts featuring Norman Ng on OncoDaily.